Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma.
ALBI
Child-Pugh score
hepatocellular carcinoma
lenvatinib
sorafenib
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
27
10
2019
revised:
23
03
2020
accepted:
10
04
2020
pubmed:
21
4
2020
medline:
21
4
2020
entrez:
21
4
2020
Statut:
ppublish
Résumé
Most patients with advanced hepatocellular carcinoma (HCC) have underlying chronic liver disease, which potentially deteriorated the liver functional reserve that often affects the patients' clinical course. We investigated and compared the changes in liver functional reserve during lenvatinib or sorafenib therapy in patients with advanced HCC. We prospectively collected medical information about patients with advanced HCC with a Child-Pugh score of 5-7 to compare the liver functional reserve during treatment in those who were treated with lenvatinib or sorafenib. We also evaluated the effect of the change in the liver functional reserve on patients' outcome. Moreover, we analyzed the contributing factors for maintaining the liver functional reserve during treatment. Patients were treated with lenvatinib (n = 45) or sorafenib (n = 157). Forty-five patients in the lenvatinib group and 135 patients in the sorafenib group were selected through a propensity score matching analysis. More patients treated with lenvatinib had a Child-Pugh score that was maintained or improved after 4 and 12 weeks compared with those treated with sorafenib (P = 0.048, P = 0.036, respectively). Lenvatinib was identified as one of the variables that was associated with maintaining Child-Pugh scores. Multivariate analysis revealed that a worsened Child-Pugh score after 4 weeks was an independent unfavorable predictive factor for overall survival. More patients treated with lenvatinib for advanced HCC maintained their liver functional reserves compared with those treated with sorafenib. Maintaining the liver functional reserve contributed to better outcomes for patients with advanced HCC.
Types de publication
Journal Article
Langues
eng
Pagination
871-884Informations de copyright
© 2020 The Japan Society of Hepatology.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30.
Yamashita T, Kitao A, Matsui O et al. Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. Hepatology 2014; 60: 1674-1685.
Song MJ, Chun HJ, do Song S et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012; 57: 1244-1250.
Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
Kudo M, Finn RS, Qin S et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial. Lancet 2018; 391: 1163-1173.
D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-231.
Terashima T, Yamashita T, Arai K et al. Response to chemotherapy improved hepatic reserve for patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis. Cancer Sci 2016; 2016: 1263-1269.
Terashima T, Yamashita T, Arai K, Kawaguchi K, Kitamura K et al. Beneficial effect of maintaining hepatic reserve during chemotherapy on the outcomes of patients with hepatocellular carcinoma. Liver Cancer 2017; 2017: 236-249.
Bruix J, Sheman M. Practice Guidelines Committee, American Association for the study of Liver Diseases. Management ofhepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
Johnson PJ, Berhane S, Kagebayashi C et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015; 33: 550-558.
Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
Llovet JM, Lencioni R. mRECIST for HCC: Performance and novel refinements. J Hepatol 2020; 72: 288-306.
Villanueva A. Hepatocellular carcinoma. N Engl J Med 2019; 380: 1450-1462.
Abou-Alfa GK, Meyer T, Cheng AL, EI-K AB, Rimassa L et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018; 379: 54-63.
Bruix J, Qin S, Merie P, Granito A, Huang YH et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389: 56-66.
Zhu AX, Kang YK, Yen CJ et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increase α-fetoprotein concentrations (REACH-2): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20: 282-296.
Kudo M. Lenvatinib may drastically change the treatment landscape of hepatocellular carcinoma. Liver Cancer 2018; 7: 1-19.
Llovet JM, Di Bisceglie AM, Bruix J et al. Design and endpoints of trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
Kuzuya T, Ishigami M, Ito T et al. Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment. Hepatol Res 2019; 49: 1054-1065.
Ogasawara S, Chiba T, Ooka Y et al. Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. Invest New Drugs 2018; 36: 332-339.
Terashima T, Yamashita T, Sunagozaka H et al. Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy. Hepatol Res 2018; 48: 956-966.
Uchikawa S, Kawaoka T, Aikata H et al. Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. Hepatol Res 2018; 48: 814-820.
Terashima T, Yamashita T, Tanaka N, Nakagawa H, Toyama T et al. Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib. Hepatol Res 2016; 46: 650-656.
Terashima T, Yamashita T, Toyama T et al. Surrogacy of time to progression for overall survival in advanced hepatocellular carcinoma treated with systemic therapy: A systematic review and meta-analysis of randomized controlled trials. Liver Cancer 2019; 8: 130-139.
Ueshima K, Nishida N, Hagiwara S, Aoki T, Minami T et al. Impact of baseline ALBI grade on the outcomes of hepatocellular carcinoma patients treated with lenvatinib: A multicenter study. Cancer 2019; 11: 952.
Kobayashi M, Kudo M, Izumi N et al. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. J Gastroenterol 2019; 54: 558-570.